Nautilus Biotechnology (NAUT) EPS (Weighted Average and Diluted) (2020 - 2026)
Nautilus Biotechnology's (NAUT) quarterly EPS (Weighted Average and Diluted) came in at -$0.12 in Q1 2026, up 7.69% year-on-year from -$0.11 in Q1 2025, and down 9.09% quarter-over-quarter from -$0.11 in Q4 2025.
Nautilus Biotechnology (NAUT) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has disclosed EPS (Weighted Average and Diluted) across 7 years of filings, most recently posting -$0.12 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.12, up 7.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.46 (up 14.81% YoY), and the FY2025 annual result was -$0.47, up 16.07% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.12 for Q1 2026 at Nautilus Biotechnology, down from -$0.11 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.1 in Q4 2022 to a low of -$0.15 in Q1 2024.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.13 (2022), against an average of -$0.13.
- Across the five-year window, EPS (Weighted Average and Diluted) surged 48.0% in 2022 and tumbled 40.0% in 2023, its largest moves.
- Nautilus Biotechnology's EPS (Weighted Average and Diluted) stood at -$0.1 in 2022, then sank by 40.0% to -$0.14 in 2023, then fell by 0.0% to -$0.14 in 2024, then grew by 21.43% to -$0.11 in 2025, then retreated by 9.09% to -$0.12 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.12 (Q1 2026), -$0.11 (Q4 2025), and -$0.11 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 0.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -0.61 |
| 10 | Nautilus Biotechnology | 289.99 Mn | 194.12 Mn | - | -0.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.12 |
| Dec 31, 2025 | -0.11 |
| Sep 30, 2025 | -0.11 |
| Jun 30, 2025 | -0.12 |
| Mar 31, 2025 | -0.13 |
| Dec 31, 2024 | -0.14 |
| Sep 30, 2024 | -0.13 |
| Jun 30, 2024 | -0.14 |
| Mar 31, 2024 | -0.15 |
| Dec 31, 2023 | -0.14 |
| Sep 30, 2023 | -0.13 |
| Jun 30, 2023 | -0.13 |
| Mar 31, 2023 | -0.12 |
| Dec 31, 2022 | -0.10 |
| Sep 30, 2022 | -0.11 |
| Jun 30, 2022 | -0.12 |
| Mar 31, 2022 | -0.13 |
| Dec 31, 2021 | -0.13 |
| Sep 30, 2021 | -0.12 |
| Jun 30, 2021 | -0.19 |